PNPLA3 polymorphism increases risk for and severity of chronic hepatitis C liver disease
| Autor: | Maen Masadeh, Vincent Petros, Arjun Nanda, Ashwani K. Singal, Muhannad Al Hanayneh, Habeeb Salameh, Matthew Maslonka |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Cirrhosis Hepatocellular carcinoma Hepatitis C virus medicine.disease_cause rs738409 Gastroenterology 03 medical and health sciences Liver disease 0302 clinical medicine Internal medicine medicine Hepatology business.industry Fatty liver Odds ratio Publication bias medicine.disease 030104 developmental biology PNPLA3 polymorphism 030211 gastroenterology & hepatology Steatohepatitis business Meta-Analysis |
| Zdroj: | World Journal of Hepatology |
| ISSN: | 1948-5182 |
| Popis: | AIM To examine the association of PNPLA3 polymorphisms in chronic hepatitis C patients and development of liver disease spectrum. METHODS Literature was searched systematically from PubMed/MEDLINE, EMBASE, and Cochrane search engines for full-length articles written in English that examined PNPLA3 polymorphism in chronic hepatitis C (CHC) patients. Studies evaluating the association of PNPLA3 polymorphism spectrum (fatty liver, steatohepatitis, cirrhosis, and hepatocellular carcinoma) of CHC were included. Pooled data are reported as OR with 95%CI. Our study endpoint was the risk of the entire liver disease spectrum including: Steatosis/fatty liver, cirrhosis, and hepatocellular carcinoma in CHC patients with PNPLA3 polymorphisms. RESULTS Of 380 studies identified, a total of 53 studies were included for full-text review. Nineteen on chronic hepatitis C were eligible for analysis. Pooled ORs for rs738409 GG compared to CC and CG among patients with fatty liver was 2.214 (95%CI: 1.719-2.853). ORs among advanced fibrosis/cirrhosis were 1.762 (95%CI: 1.258-2.468). Similar odds ratios among hepatocellular carcinoma patients were 2.002 (95%CI: 1.519-2.639). Pooled ORs for rs738409 GG and CG compared to CC among patients with fatty liver were 1.750 (95%CI: 1.542-1.986). Pooled ORs for advanced fibrosis/cirrhosis patients were 1.613 (95%CI: 1.211-2.147). All analyses were homogenous and without publication bias except one. The associations were maintained after adjusting for publication bias and heterogeneity. CONCLUSION PNPLA3 polymorphisms have strong association with increased risk and severity of the liver disease spectrum in CHC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|